Compare Stitch Fix Inc (SFIX) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stitch Fix Inc vs Smith & Nephew plc — how do they compare? Stitch Fix Inc trades at $2.84 (market cap $366.07M), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: Smith & Nephew plc is far larger — about 30.3× Stitch Fix Inc's market cap, and Smith & Nephew plc pays a 2.95% dividend while Stitch Fix Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Stitch Fix Inc for 31 Days and Smith & Nephew plc for 121 Days on average.
| SFIX | SNN | |
|---|---|---|
Market Cap | $366.07M | $11.10B |
Volume | 5,152,008 | 1,051,703 |
Sector | Consumer Cyclical | Health |
52-Week High | $5.64 | $37.17 |
52-Week Low | $2.16 | $26.42 |
Typical Hold Time | 31 Days | 121 Days |
Enterprise Value | $261.88M | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Stitch Fix (SFIX) trades at $2.73, showing no change in the latest session. The stock faces bearish technical signals with recent earnings beats overshadowed by weak forward guidance. Revenue has stabilized around $1.3 billion, but profitability remains elusive with negative net income margins. Recent news highlights multiple law firm investigations and a significant post-earnings decline due to cautious fiscal 2027 outlook.
The outlook remains challenging with Wall Street showing cautious sentiment (24% buy ratings). While AI initiatives show promise for customer engagement, declining active clients and ongoing profitability concerns present significant headwinds. The consensus price target of $3.40 suggests limited upside potential amid execution risks and competitive pressures.
SNN trades at $26.96, up 0.26% on the day, but near its 52-week low amid a bearish technical signal. Recent earnings have mostly beaten expectations, with Q2 2026 EPS of $0.946 exceeding the $0.939 estimate. Revenue grew to $6.16B in 2025, and net income margin improved to 10.08%. The company continues to launch new medical products, such as the EVOS PELVIC System, to drive growth.
The outlook is mixed; strong fundamentals and product innovation support long-term value, but near-term price pressure and analyst caution pose risks. Investors should weigh robust profitability against competitive threats and recent management changes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Stitch Fix Inc
Stitch Fix Inc offers personal style service for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandises with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types and price points including Women's, Petite, Maternity, Men's and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry and handbags, and sells merchandise across various range of price points.
Read more on SFIX →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
